Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 13, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

How Will PSMAddition Impact the Management of Prostate Cancer?

Valentina Marulanda-Corzo1, Aaron N Holmes2, Vinay K Giri3

  • 1Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York City, NY, USA.

European Urology Focus
|June 11, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Top advances of the year: Radiopharmaceutical therapy for prostate cancer.

Cancer·2026
Same author

PSMA-PET Total Tumor Volume Response: Ready for Prime Time or a Work in Progress?

European urology·2026
Same author

Temporal Trends in the Frequency of Concomitant Cancer and Cerebrovascular Disease Diagnoses in the United States.

Neurology. Clinical practice·2026
Same author

PET-guided Assessment of Amyloid Clearance and Outcomes in a Real-World Cohort of Patients with Alzheimer Disease undergoing Anti-Amyloid Therapy.

AJNR. American journal of neuroradiology·2026
Same author

Cross-Platform Concordance of Quantitative Amyloid PET Z-Scores in a Real-World Clinical Cohort of Patients with Cognitive Impairment and Suspected Alzheimer Disease.

AJNR. American journal of neuroradiology·2026
Same author

Stereotactic Body Radiation Therapy (SBRT)-Induced 68Ga-PSMA PET Bone Flare.

Clinical nuclear medicine·2026
This summary is machine-generated.

Adding 177Lu-PSMA-617 radionuclide therapy to androgen deprivation therapy plus an androgen receptor pathway inhibitor improves cancer control for metastatic prostate cancer patients. This initial treatment strategy enhances radiographic progression-free survival.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Medical Imaging

Background:

  • Metastatic prostate cancer (mPC) treatment typically involves androgen deprivation therapy (ADT) with an androgen receptor pathway inhibitor (ARPI).
  • 177Lu-PSMA-617 shows efficacy in later-stage disease, but earlier use may prevent resistance.
  • Prostate-specific membrane antigen (PSMA)-targeted therapies are emerging for mPC.

Purpose of the Study:

  • To evaluate the efficacy of adding 177Lu-PSMA-617 to first-line ADT + ARPI in metastatic prostate cancer.
  • To assess the impact of early 177Lu-PSMA-617 integration on radiographic progression-free survival (rPFS).

Main Methods:

  • The PSMAddition trial was a phase 3 study.
  • Participants received either first-line 177Lu-PSMA-617 plus ADT + ARPI or ADT + ARPI alone.
Keywords:
(177)Lu-PSMA-617Androgen Receptor Pathway Inhibitor (ARPI)Androgen deprivation therapy (ADT)Metastatic Androgen Pathway Modulator Naive (mAPMN)Metastatic Androgen Pathway Modulator Sensitive (mAPMS)PSMAPSMAddition TrialPhase III Clinical TrialProstate cancerTargeted Radionuclide Therapy

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Experiment Videos

Last Updated: Jun 13, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

  • Radiographic progression-free survival was the primary endpoint.

    • Main Results:

    • First-line 177Lu-PSMA-617 added to ADT + ARPI significantly improved rPFS compared to ADT + ARPI alone.
    • The addition of 177Lu-PSMA-617 demonstrated enhanced cancer control in metastatic prostate cancer.

    Conclusions:

    • Early integration of 177Lu-PSMA-617 into the upfront treatment of metastatic prostate cancer improves outcomes.
    • Further research is needed to understand long-term health economic and quality-of-life implications.
    • 177Lu-PSMA-617 represents a promising therapeutic option for initial mPC management.